Document:

EX-10.26

 Exhibit 10.26 

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment No. 1”), made and entered into this 10th day of February, 2016 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product
Development, Inc. (the “Company”), and B. Judd Hartman (the “Executive”). 
 WHEREAS, the Company and
Executive are parties to that certain Employment Agreement dated as of April 10, 2012 (the “Employment Agreement”); and 

WHEREAS, the parties desire to amend the Employment Agreement as set forth herein. 

NOW, THEREFORE, that for and in consideration of the foregoing recitals, the mutual promises, covenants and conditions
contained herein, and other good and valid consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

1.     Capitalized Terms. Capitalized terms used in this Amendment No. 1 and not defined herein shall have the
meaning given to them in the Employment Agreement. 
 2.     Amendment. The second sentence of Section 1(c)
of the Employment Agreement be and hereby is deleted in its entirety and replaced in full by the following sentence: 
 “Executive
shall devote substantially all of Executive’s working time and efforts to the business and affairs of the Company (which shall include service to its subsidiaries and affiliates) and shall not engage in outside business activities (including
serving on outside boards or committees) without the consent of the Board, provided that Executive shall be permitted to (i) manage Executive’s personal, financial and legal affairs, (ii) participate in trade associations,
(iii) serve on the board or directors of one for-profit enterprise (whether public or private), subject to the consent of the Chief Executive Officer of the Company, such consent not to be unreasonably
withheld, and (iv) serve on the board of directors of not-for-profit or tax-exempt charitable organizations, in each case,
subject to Section 5 and the Proprietary Information Agreement and provided that such activities do not interfere with Executive’s performance of Executive’s duties and responsibilities hereunder.” 

3.     Entire Agreement. This Amendment No. 1 constitutes the entire agreement of the parties with respect to
the subject matter hereof and supersedes all prior or contemporaneous agreements or understandings, whether written or oral, relating to the same. 

4.     Binding Effect. The Employment Agreement, as herein amended, shall continue in full force and effect. 

 IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 as of the date first
above written. 
  

					
	PHARMACEUTICAL PRODUCT
	DEVELOPMENT, LLC
		
	By:	 	 /s/ David S.
Simmons                                    

	Name:	 	 David S. Simmons

	Title:	 	 Chief Executive Officer

	  
 B. JUDD
HARTMAN
  

/s/ B. Judd Hartman                    
                        (SEAL)

  

			
	Consented and agreed to by Parent:
	
	JAGUAR HOLDING COMPANY I
		
	By:	 	 /s/ David S. Simmons

	Name:	 	David S. Simmons
	Title:	 	Chairman and Chief Executive Officer

  
 2EX-10.27

 Exhibit 10.27 

 

			
	Strictly Confidential	  	Execution Version

 ASSIGNMENT AND ASSUMPTION AGREEMENT 

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), dated as of May 11, 2017, is entered into by and among
Jaguar Holding Company I, a Delaware corporation (the “Assignor”), Eagle Holding Company I, a Delaware corporation (the “Assignee”), Pharmaceutical Product Development, LLC, a Delaware limited liability company
(“PPD”) and B. Judd Hartman (the “Executive”). Capitalized or other terms used and not defined herein shall have the meanings ascribed to them in that certain Agreement and Plan of Merger, dated as of April 26, 2017
(as amended, restated, modified or supplemented from time to time, the “Merger Agreement”), by and among the Assignee, Eagle Holding Company II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Assignee
(“Holdings”), Eagle Reorganization Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Holdings, Eagle Buyer, Inc., a Delaware corporation and the Assignor. 

In consideration of the mutual covenants and conditions as hereinafter set forth, each of the parties hereto hereby agree as follows: 

1.    Assignment of Employment Agreement. 

a)     Assignment. The Assignor hereby irrevocably and absolutely transfers and assigns to the
Assignee, and the Assignee hereby accepts and assumes from the Assignor, the Assignor’s rights and obligations under that certain Employment Agreement, dated as of April 10, 2012, as amended, by and among PPD, the Assignor and the Executive
(the “Employment Agreement”), with effect from the Effective Time (the “Assignment”). The Assignee agrees with the Assignor to perform and satisfy when due all obligations of the Employment Agreement, and further
agrees to be bound by the terms and provisions of the Employment Agreement applicable to the Assignor thereunder. 

b)     Consent of Executive. By executing this Agreement the Executive hereby provides written
consent to the Assignment. 
 c)     Parent. Each of the parties hereto agrees that, with effect
from the Assignment, references to “Parent” in the Employment Agreement shall be deemed to be references to the Assignee. 

2.     Governing Law. This Agreement, and all claims or causes of action based upon, arising out of, or
related to this Agreement or the transactions contemplated hereby, shall be governed by, and construed in accordance with, the laws of the State of North Carolina, without giving effect to principles or rules of conflict of laws to the extent such
principles or rules would require or permit the application of laws of another jurisdiction. 
 3.    
Jurisdiction. Each of the parties hereto (i) consent to submit itself to the personal jurisdiction and venue of any Federal court located in the State of North Carolina or any North Carolina state court with respect to any suit
relating to or arising out of this Agreement or any of the transactions contemplated hereby, (ii) agrees that it will not attempt to defeat or deny such personal jurisdiction or venue by motion or otherwise, (iii) agrees that it will not
bring any such suit in any court other than a Federal or State court sitting in the State of North Carolina, (iv) irrevocably agrees that any such suit (whether at law, in equity, in contract, in tort or otherwise) shall be heard and determined
exclusively in such Federal or State court sitting in the State of North Carolina and (v) agrees to service of process in any such Action in any manner prescribed by the laws of the State of North Carolina. Nothing herein contained shall be
deemed to affect the right of any party to serve process in any manner permitted by Law or to commence legal proceedings or otherwise proceed against any other party in any other jurisdiction, in each case, to enforce judgments obtained in any
Action brought pursuant to this Section 3. 

 4.     Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND
AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

5.     Further Assurances. Each party hereto shall cooperate and shall take such further action and shall
execute and deliver such further documents as may be reasonably requested by the other parties hereto in order to carry out the provisions and purposes of this Agreement. 

6.     Successors and Assigns. This Agreement and all the provisions hereof shall be binding upon and shall
inure to the benefit of the parties hereto and their respective successors and permitted assigns. Nothing in this Agreement is intended to give any other Person any right, remedy or claim under this Agreement 

7.     Counterparts. This Agreement may be executed in any number of counterparts (which delivery may be via
facsimile transmission or e-mail if in .pdf format), each of which shall be deemed an original, but all of which together shall constitute a single instrument. 

[Remainder of page intentionally left blank] 

  
 2 

 IN WITNESS WHEREOF, the undersigned, intending to be legally bound hereby, have duly
executed this Agreement as of the date first written above. 
  

					
	ASSIGNOR:
	
	JAGUAR HOLDING COMPANY I
		
	By:	 	 /s/ B. Judd Hartman

		 	Name:	 	B. Judd Hartman
		 	Title:	 	General Counsel and Secretary

  
 [Signature Page to
Assignment and Assumption Agreement] 

 
					
	ASSIGNEE:
	
	EAGLE HOLDING COMPANY I
		
	By:	 	 /s/ P. Hunter Philbrick

		 	Name:	 	P. Hunter Philbrick
		 	Title:	 	Vice President

  
 [Signature Page to
Assignment and Assumption Agreement] 

	
	Accepted and acknowledged:
	
	EXECUTIVE:
	
	B. JUDD HARTMAN
	
	 /s/ B. Judd Hartman

  
 [Signature Page to
Assignment and Assumption Agreement] 

					
	Accepted and acknowledged:
	
	PPD:
	
	PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
		
	By:	 	 /s/ B. Judd Hartman

		 	Name:	 	B. Judd Hartman
		 	Title:	 	General Counsel and Secretary

  
 [Signature Page to
Assignment and Assumption Agreement]EX-10.28

 Exhibit 10.28 

EXECUTION VERSION 

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the “Amendment No. 2”), made and entered into this 1st day of
April, 2018 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and B. Judd
Hartman (the “Executive”). 
 WHEREAS, the Company and Executive are parties to that certain Employment Agreement
dated as of April 10, 2012 as amended by that certain Amendment No. 1 to the Employment Agreement dated as of February 10, 2016 (the “Employment Agreement”); and 

WHEREAS, the parties desire to further amend the Employment Agreement as set forth herein. 

NOW, THEREFORE, that for and in consideration of the foregoing recitals, the mutual promises, covenants and conditions contained
herein, and other good and valid consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

1.    Capitalized Terms. Capitalized terms used in this Amendment No. 2 and not defined herein shall have the
meaning given to them in the Employment Agreement. 
 2.    Amendment. The third sentence of Section 2(b) of
the Employment Agreement be and hereby is deleted in its entirety and replaced in full by the following sentence: 
 “The Annual Bonus
shall be based on the achievement of applicable Company and individual performance metrics set forth in or established under the Company’s Senior Executive Incentive Compensation Plan, as it may be amended from time to time.” 

3.    Entire Agreement. This Amendment No. 2 constitutes the entire agreement of the parties with respect to
the subject matter hereof and supersedes all prior or contemporaneous agreements or understandings, whether written or oral, relating to the same. 

4.    Binding Effect. The Employment Agreement, as herein amended, shall continue in full force and effect. 

 IN WITNESS WHEREOF, the parties have executed this Amendment No. 2 as of the date first
above written. 
  

			
	PHARMACEUTICAL PRODUCT
	DEVELOPMENT, LLC
		
	By:	 	 /s/ David S. Simmons

	Name:	 	David S. Simmons
	Title:	 	Chief Executive Officer
	
	 B. JUDD HARTMAN
  

/s/ B. Judd Hartman

  

			
	Consented and agreed to by Parent:
	
	EAGLE HOLDING COMPANY I
		
	By:	 	 /s/ David S. Simmons

	Name:	 	David S. Simmons
	Title:	 	Chairman and Chief Executive Officer

  
 [Signature Page to
Employment Agreement Amendment]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]